281 related articles for article (PubMed ID: 32345265)
1. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Chiang AC; Fernandes AW; Pavilack M; Wu JW; Laliberté F; Duh MS; Chehab N; Subramanian J
BMC Cancer; 2020 Apr; 20(1):356. PubMed ID: 32345265
[TBL] [Abstract][Full Text] [Related]
2. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
3. Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study.
Turnsek N; Devjak R; Edelbaher N; Osrajnik I; Unk M; Vidovic D; Jeric T; Janzic U
Radiol Oncol; 2022 Aug; 56(3):371-379. PubMed ID: 35853681
[TBL] [Abstract][Full Text] [Related]
4. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
[TBL] [Abstract][Full Text] [Related]
5. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.
Shenolikar R; Liu S; Shah A; Tse J; Cao Y; Near A
Cancer Med; 2023 Jan; 12(1):159-169. PubMed ID: 35702932
[TBL] [Abstract][Full Text] [Related]
7. Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
Kraskowski O; Stratmann JA; Wiesweg M; Eberhardt W; Metzenmacher M; Schmid KW; Herold T; Schildhaus HU; Darwiche K; Aigner C; Stuschke M; Laue K; Zaun G; Kasper S; Hense J; Sebastian M; Schuler M; Pogorzelski M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9243-9252. PubMed ID: 37198447
[TBL] [Abstract][Full Text] [Related]
8. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.
Wagener-Ryczek S; Heydt C; Süptitz J; Michels S; Falk M; Alidousty C; Fassunke J; Ihle MA; Tiemann M; Heukamp L; Wolf J; Büttner R; Merkelbach-Bruse S
BMC Cancer; 2020 May; 20(1):408. PubMed ID: 32397977
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
10. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
11. Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment.
Iacono D; Osman GA; Migliorino MR; Grillo L; Remotti D; Nunnari J; Ricciardi S; Rossi A; Mancuso A; Graziano P; Di Lorenzo A; Bronzini M; Signora M; Leone A
Am J Clin Oncol; 2019 Nov; 42(11):845-850. PubMed ID: 31644442
[TBL] [Abstract][Full Text] [Related]
12. Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure.
Mizuno T; Horinouchi H; Watanabe S; Sato J; Morita R; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2020 Apr; 11(4):1038-1044. PubMed ID: 32077630
[TBL] [Abstract][Full Text] [Related]
13. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
Agulnik JS; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Small D
Curr Oncol; 2021 Dec; 28(6):5179-5191. PubMed ID: 34940073
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India.
Garg A; Batra U; Choudhary P; Jain D; Khurana S; Malik PS; Muthu V; Prasad KT; Singh N; Suri T; Mohan A
Curr Probl Cancer; 2020 Jun; 44(3):100570. PubMed ID: 32498966
[TBL] [Abstract][Full Text] [Related]
15. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.
Minari R; Mazzaschi G; Bordi P; Gnetti L; Alberti G; Altimari A; Gruppioni E; Sperandi F; Parisi C; Guaitoli G; Bettelli S; Longo L; Bertolini F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Fiorentino M; Tiseo M;
Clin Lung Cancer; 2020 Sep; 21(5):e464-e473. PubMed ID: 32276870
[TBL] [Abstract][Full Text] [Related]
16. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
17. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
18. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
19. Study of patient characteristics, treatment patterns,
Winfree KB; Sheffield KM; Cui ZL; Sugihara T; Feliciano J
Curr Med Res Opin; 2022 Jan; 38(1):91-99. PubMed ID: 34544302
[TBL] [Abstract][Full Text] [Related]
20. Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.
Kashiwabara K; Fujii S; Tsumura S; Sakamoto K
J Cancer Res Clin Oncol; 2021 Jan; 147(1):287-293. PubMed ID: 32761377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
